Binnopharm Group, a pharmaceutical company that combines the core assets of Sistema, will open a modern R&D center in the Krasnogorsk district of the Moscow Region. Thanks to it, more than 100 new drugs may enter the market by 2025, the Ministry of Investment, Industry and Science of the region said.

"The new R&D center will strengthen the region's research base in pharmaceuticals. The total investment in the project is estimated at 2.5 billion rubles," said Ekaterina Zinovieva, head of the ministry.

The project will consolidate the research units of all the company's enterprises. In addition, there will be centers for pharmaceutical development of chemically synthesized drugs and biotechnological preparations. The total area of the R&D centre will amount to 12 thousand square meters and the number of staff will be about 450 specialists.

The Pharmaceutical Development Center, which also includes a pilot site for the production of solid and soft dosage forms, will start operating in the first quarter of 2022. The next phase of the project will include a biotech drug development center and pilot production.

"The project is unique in that it will unite chemical and biotechnological laboratories for drug development in one place. By concentrating intellectual competencies and equipping the development centers with state-of-the-art equipment, we will be able to bring the drug development process to a new level and create drugs of any complexity, including biotech drugs with no domestic analogues. Thanks to the R&D centre, we will be able to renew Binnopharm Group's portfolio of drugs by more than 10% annually," said Rustem Muratov, General Director of Binnopharm Group.

It is specified that the capacity of the R&D center will enable the launch of more than 100 new drugs in dermatology, neurology, gynecology, pediatrics and other therapeutic groups by 2025. Establishment of a production site and quality control laboratory licensed in accordance with the requirements of the European Union and the US Food and Drug Administration (FDA) will enable Binnopharm Group to develop products to be launched not only in Russian, but also in foreign markets.

Made in Russia // Made in Russia